Coherus Biosciences Inc (NASDAQ: CHRS) has experienced a decline in its stock price by -6.57 compared to its previous closing price of 0.79. However, the company has seen a fall of -9.12% in its stock price over the last five trading days. globenewswire.com reported 2025-03-25 that REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois.
Is It Worth Investing in Coherus Biosciences Inc (NASDAQ: CHRS) Right Now?
Coherus Biosciences Inc (NASDAQ: CHRS) has a higher price-to-earnings ratio of 4.26x compared to its average ratio, The 36-month beta value for CHRS is at 1.05. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CHRS is 111.29M, and currently, shorts hold a 29.19% of that float. The average trading volume for CHRS on April 11, 2025 was 1.96M shares.
CHRS’s Market Performance
CHRS stock saw a decrease of -9.12% in the past week, with a monthly decline of -24.27% and a quarterly a decrease of -50.85%. The volatility ratio for the week is 15.02%, and the volatility levels for the last 30 days are 11.05% for Coherus Biosciences Inc (CHRS).. The simple moving average for the past 20 days is -14.51% for CHRS’s stock, with a -38.59% simple moving average for the past 200 days.
Analysts’ Opinion of CHRS
Many brokerage firms have already submitted their reports for CHRS stocks, with UBS repeating the rating for CHRS by listing it as a “Neutral.” The predicted price for CHRS in the upcoming period, according to UBS is $1.50 based on the research report published on August 16, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CHRS reach a price target of $11. The rating they have provided for CHRS stocks is “Outperform” according to the report published on November 17th, 2023.
CHRS Trading at -26.43% from the 50-Day Moving Average
After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.55% of loss for the given period.
Volatility was left at 11.05%, however, over the last 30 days, the volatility rate increased by 15.02%, as shares sank -16.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.16% lower at present.
During the last 5 trading sessions, CHRS fell by -9.12%, which changed the moving average for the period of 200-days by -54.47% in comparison to the 20-day moving average, which settled at $0.8682. In addition, Coherus Biosciences Inc saw -46.22% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CHRS
Current profitability levels for the company are sitting at:
- -0.39 for the present operating margin
- 0.55 for the gross margin
The net margin for Coherus Biosciences Inc stands at 0.11. The total capital return value is set at -0.63.
Based on Coherus Biosciences Inc (CHRS), the company’s capital structure generated 1.96 points at debt to capital in total, while cash flow to debt ratio is standing at -0.08. The debt to equity ratio resting at -2.04. The interest coverage ratio of the stock is -3.86.
Currently, EBITDA for the company is 60.94 million with net debt to EBITDA at -1.69. When we switch over and look at the enterprise to sales, we see a ratio of 0.86. The receivables turnover for the company is 2.4for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.21.
Conclusion
In conclusion, Coherus Biosciences Inc (CHRS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
